Detalhe da pesquisa
1.
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.
J Transl Med
; 22(1): 329, 2024 Apr 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38570798
2.
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.
Int J Mol Sci
; 25(7)2024 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38612563
3.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34167578
4.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38489861
5.
Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients-A Retrospective Observational Study.
Cancers (Basel)
; 15(13)2023 Jun 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37444532
6.
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer.
Cancers (Basel)
; 15(23)2023 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38067208
7.
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Clin Cancer Res
; 29(14): 2714-2724, 2023 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37125965
8.
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease.
Drugs Context
; 112022.
Artigo
Inglês
| MEDLINE | ID: mdl-36303600
9.
Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study.
Oncotarget
; 13: 686-693, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35574217
10.
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease.
Drugs Context
; 112022.
Artigo
Inglês
| MEDLINE | ID: mdl-35975031
11.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Eur J Cancer
; 150: 224-231, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33934059
12.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33827906